• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:AU2007274040A1
    申请号:U2007274040
    申请日:2007-07-13
    公开日:2008-01-17
    发明作者:David John Duncalf；Andrew James Elphick；Alison Jayne Foster；James Long；Steven Paul Rannard；John Staniforth；Dong Wang
    申请人:Unilever PLC；
    IPC主号:A61K9-16
    专利说明:
    WO 2008/007151 1 PCT/GB2007/050408 Processes for Preparing Pharmaceutical Compositions Field of the Invention The present invention relates to improvements relating to pharmaceutical 5 compositions. In particular it relates to pharmaceutically active compositions and precursors therefor which fall within the group of so-called "triptans". Background of the Invention Triptans are a family of tryptamine-based drugs used, for example, in the treatment 10 of migraine and cluster headaches. They are selective serotonin receptor agonists and their mechanism of action is attributed to their serotonin agonist activity at 5 HTIB and 5-HTD receptors in the body, whether centrally, for example in the dorsal horn of the brain, and/or peripherally, for example at cranial blood vessels. Although other dosing regimes are possible, it is felt that triptans are preferably 15 administered to a patient within twenty minutes of the onset of a headache. Triptans include sumatriptan (Imitrex@, Imigran@), rizatriptan (Maxalt@), naratriptan (Amerge@, Naramig@), zolmitriptan (Zomig@), eletriptan (Relpax@), almotriptan (Axert@, Almogran®), and frovatriptan (Frova@, Migard@). 20 Many triptans exhibit low water solubility and are practically insoluble in water. This hinders their effective use, particularly for oral delivery in base form and water soluble salt forms are preferred, such as sumatriptan succinate, rizatriptan benzoate, naratriptan hydrochloride, eletriptan hydrobromide, almotriptan malate, frovatriptan 25 succinate. WO 2004/011537 describes the formation of solid, porous beads comprising a three dimensional open-cell lattice of a water-soluble polymeric material. These are typically "templated" materials formed by the removal of both water and a non 30 aqueous dispersed phase from a high internal phase emulsion (HIPE) which has a polymer dissolved in the aqueous phase. The beads are formed by dropping the HIPE emulsion into a low temperature fluid such as liquid nitrogen, then freeze drying the particles formed to remove the bulk of the aqueous phase and the WO 2008/007151 - 2 - PCT/GB2007/050408 dispersed phase. This leaves behind the polymer in the form of a "skeletal" structure. The beads dissolve rapidly in water and have the remarkable property that a water-insoluble component dispersed in the dispersed phase of the emulsion prior to freezing and drying can also be dispersed in water on solution of the polymer 5 skeleton of the beads. WO 2005/011636 discloses a non-emulsion based spray drying process for forming "solid amorphous dispersions" of drugs in polymers. In this method a polymer and a low-solubility drug are dissolved in a solvent and spray-dried to form dispersions 10 in which the drug is mostly present in an amorphous form rather than in a crystalline form. Unpublished co-pending applications (GB 0501835 of 28 January 2005 and GB 0613925 filed on 13 July 2006) describe how materials which will form a nano 15 dispersion in water can be prepared, preferably by a spray-drying process. In the first of these applications the water insoluble materials is dissolved in the solvent phase of an emulsion. In the second, the water-insoluble materials are dissolved in a mixed solvent system and co-exist in the same phase as a water-soluble structuring agent. In both cases the liquid is dried above ambient temperature (above 20*C), 20 such as by spray drying, to produce particles of the structuring agent, as a carrier, with the water-insoluble materials dispersed therein. When these particles are placed in water they dissolve, forming a nano-dispersion of the water-insoluble material with particles typically below 300 nm. This scale is similar to that of virus particles, and the water-insoluble material behaves as though it were in solution. 25 In the present application the term "ambient temperature" means 20*C and all percentages are percentages by weight unless otherwise specified. Brief Description of the Invention 30 We have now determined that both the emulsion-based and the single-phase method can be used to produce a water-soluble, nano-disperse form of a triptan.
    WO 2008/007151 - - PCT/GB2007/050408 Accordingly, the present invention provides a process for the production of a composition comprising a water-insoluble triptan which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble triptan, 5 ii) a water soluble carrier, and iii) a solvent for each of the triptan and the carrier; and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the triptan in the carrier. 10 The preferred method of particle sizing for the dispersed products of the present invention employs a dynamic light scattering instrument (Nano S, manufactured by Malvern Instruments, UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4mW Helium-Neon laser to illuminate a standard optical quality UV cuvette containing a suspension of material. The particle sizes quoted in this 15 application are those obtained with that apparatus using the standard protocol. Particle sizes in solid products are the particle sizes inferred from the measurement of the particle size obtained by solution of the solid in water and measurement of the particle size. 20 Preferably, the peak diameter of the water-insoluble triptan is below 1500 nm. More preferably the peak diameter of the water-insoluble triptan is below 1000 nm, most preferably below 800 nm. In a particularly preferred embodiment of the invention the median diameter of the water-insoluble triptan is in the range 400 to 1000 nm, more preferably 500 to 800 nm. 25 Advantageous compositions obtainable by the process of the present invention comprise a water-insoluble triptan and a water soluble carrier which comprises triptan particles of 750 nm average particle size dispersed in the carrier. It is believed that reduction of the particle size in the eventual nano-dispersion has 30 significant advantages in improving the availability of the otherwise water-insoluble material. This is believed to be particularly advantageous where an improved bio availability is sought, or, in similar applications where high local concentrations of WO 2008/007151 PCT/GB2007/050408 the material are to be avoided. Moreover it is believed that nano-dispersions with a small particle size are more stable than those with a larger particle size. In the context of the present invention, "water insoluble" as applied to the triptan 5 means that its solubility in water is less than 25 g/L. "Water insoluble triptan" may also mean that the solubility of the triptan is less than 20 or less than 15 g/L. Preferably, the water insoluble triptan has solubility in water at ambient temperature (20"C) less than 5 g/L preferably of less than 1 g/L, especially preferably less than 150 mg/L, even more preferably less than 100 mg/L. This solubility level provides 10 the intended interpretation of what is meant by water-insoluble in the present specification. Preferred water-insoluble triptans include base forms of sumatriptan, rizatriptan, naratriptan, eletriptan, almotriptan, frovatriptan and zolmitriptan and water 15 insoluble derivatives of these compounds. Preferred carrier materials are selected from the group consisting of water-soluble organic and inorganic materials, surfactants, polymers and mixtures thereof. 20 A further aspect of the present invention provides a process for preparing a triptan composition comprising a water-insoluble triptan and a water-soluble carrier, which comprises the steps of: a) forming an emulsion comprising: i) a solution of the triptan in a water-immiscible solvent for the same, 25 and ii) an aqueous solution of the carrier; and b) drying the emulsion to remove water and the water-immiscible solvent to obtain a substantially solvent-free nano-dispersion of the triptan in the carrier. 30 For convenience, this class of method is referred to herein as the "emulsion" method.
    WO 2008/007151 PCT/GB2007/050408 A further aspect of the present invention provides a process for preparing a triptan composition comprising a water insoluble triptan and a water-soluble carrier which comprises the steps of: a) providing a single phase mixture comprising: 5 i) at least one non-aqueous solvent, ii) optionally, water, iii) a water-soluble carrier material soluble in the mixture of (i) and (ii), and iv) a water-insoluble triptan which is soluble in the mixture of (i) and (ii); 10 and b) drying the solution to remove water and the water miscible solvent to obtain a substantially solvent-free nano-dispersion of the triptan in the carrier. For convenience, this class of method is referred to herein as the "single-phase" 15 method. In the context of the present invention substantially solvent free means within limits accepted by international pharmaceutical regulatory bodies (eg FDA, EMEA) for residual solvent levels in a pharmaceutical product and/or that the free solvent 20 content of the product is less than 15% wt, preferably below 10% wt, more preferably below 5% wt and most preferably below 2% wt. In the context of the present invention it is essential that both the carrier material and the triptan are essentially fully dissolved in their respective solvents prior to the 25 drying step. It is not within the ambit of the present specification to teach the drying of slurries. For the avoidance of any doubt, it is therefore the case that the solids content of the emulsion or the mixture is such that over 90% wt, preferably over 9 5 %, and more preferably over 98% of the soluble materials present is in solution prior to the drying step. 30 In relation to the methods mentioned above, the preferred triptan and the preferred carrier materials are as described above and as elaborated on in further detail below.
    WO 2008/007151 PCT/GB2007/050408 Similarly the preferred physical characteristics of the material are as described above. The "single phase" method where both the triptan and the carrier material are 5 dissolved in a phase comprising at least one other non-aqueous solvent (and optional water) is preferred. This is believed to be more efficacious in obtaining a smaller particle size for the nano-disperse triptan. Preferably, the drying step simultaneously removes both the water and other solvents and, more preferably, drying is accomplished by spray drying at above ambient temperature. 10 The products obtainable by the process aspects of the present invention are suitable for use in the preparation of medicaments for treatment of migraines and headaches, especially cluster headaches. 15 A further aspect of the present invention provides a method for the preparation of a medicament for use in the treatment of migraines and headaches, especially cluster headaches, which comprises the step of preparing a composition according to the present invention. 20 Detailed Description of the Invention Various preferred features and embodiments of the present invention are described in further detail below. Triptans 25 As noted above the preferred water-insoluble triptans include sumatriptan, rizatripta, naratriptan, zolmitriptan, eletriptan, almotriptan, frovatriptan and derivatives and mixtures thereof. These can be present as the sole pharmaceutically active ingredient in compositions according to the present invention or be together with other drugs to provide a so-called "combination therapy". 30 As an illustrative example, it would be beneficial to provide a combination of a triptan, such as Sumatriptan, and a further an agent, for example an NSAID such as diclofenac, ibuprofen or naproxen, paracetamol, or other analgesic agents such as WO 2008/007151 PCT/GB2007/050408 for example, codeine or other anti-nausea agents such as for example, diphenhydramine or ondansetron. Water-Dispersible Product Form 5 The present invention provides a method for obtaining a water-dispersible form of an otherwise water-insoluble material. This is prepared by forming a not wholly aqueous intermediate emulsion or solution in which both a water-soluble carrier material and the water insoluble triptan are dissolved. On removal of solvents the insoluble triptan is left dispersed through the water-soluble carrier material. Suitable 10 carrier materials are described in further detail below. The structure of the material obtained after the drying step is not well understood. It is believed that the resulting dry materials are not encapsulates, as discrete macroscopic bodies of the water-insoluble materials are not present in the dry 15 product. Neither are the dry materials "dry emulsions" as little or none of the volatile solvent comprising the "oil" phase of the emulsion remains after the drying step. On addition of water to the dry product the emulsion is not reformed, as it would be with a "dry emulsion". It is also believed that the compositions are not so called solid solutions, as with the present invention the ratios of components 20 present can be varied without loss of the benefits. Also from X-ray and DSC studies, it is believed that the compositions of the invention are not solid solutions, but comprise nano-scale, phase-separated mixtures. Further, from X-ray powder diffraction studies it is believed that the triptan nano-particle material produced is in crystalline form and not amorphous form and it is believed to be predominantly 25 or entirely the same crystalline form as the starting material. Preferably, the compositions produced after the drying step will comprise the triptan and the carrier in a weight ratio of from 1:500 to 1:1 (as triptan:carrier), 1:100 to 1:1 being preferred. Typical levels of around 10-50% wt water-insoluble 30 triptan and 90-50% wt carrier can be obtained by spray drying.
    WO 2008/007151 PCT/GB2007/050408 -8 By the method of the present invention the particle size of the triptan materials can be reduced to below 1000 nm and may be reduced to around 100 nm. Preferred particle sizes are in the range 400-800 nm. 5 "Emulsion" Preparation Method In one preferred method according to the invention the solvent for the water insoluble triptan is not miscible with water. On admixture with water it therefore can form an emulsion. 10 Preferably, the non-aqueous phase comprises from about 10% to about 95% v/v of the emulsion, more preferably from about 20% to about 68% v/v. The emulsions are typically prepared under conditions which are well known to those skilled in the art, for example, by using a magnetic stirring bar, a homogeniser, 15 or a rotational mechanical stirrer. The emulsions need not be particularly stable, provided that they do not undergo extensive phase separation prior to drying. Homogenisation using a high-shear mixing device is a particularly preferred way to make an emulsion in which the aqueous phase is the continuous phase. It is believed 20 that this avoidance of coarse emulsion and reduction of the droplet size of the dispersed phase of the emulsion, results in an improved dispersion of the "payload" material in the dry product. In a preferred method according to the invention a water-continuous emulsion is 25 prepared with an average dispersed-phase droplet size (using the Malvern peak intensity) of between 500 nm and 5000 nm. We have found that an Ultra-Turrux T25 type laboratory homogenizer (or equivalent) gives a suitable emulsion when operated for more than a minute at above 10,000 rpm. 30 There is a directional relation between the emulsion droplet size and the size of the particles of the payload material, which can be detected after dispersion of the materials of the invention in aqueous solution. We have determined that an increase WO 2008/007151 PCT/GB2007/050408 in the speed of homogenization for precursor emulsions can decrease final particle size after re-dissolution. It is believed that the re-dissolved particle size can be reduced by nearly one half 5 when the homogenization speed increased from 13,500 rpm to 21,500 rpm. The homogenization time is also believed to play a role in controlling re-dissolved particle size. The particle size again decreases with increase in the homogenization time, and the particle size distribution become broader at the same time. 10 Sonication is also a particularly preferred way of reducing the droplet size for emulsion systems. We have found that a Hert Systems Sonicator XL operated at level 10 for two minutes is suitable. It is believed that ratios of components which decrease the relative concentration of 15 the triptan to the solvents and/or the carrier give a smaller particle size. "Single Phase" Preparation Method In an alternative method according to the present invention both the carrier and the triptan are soluble in a non-aqueous solvent or a mixture of such a solvent with 20 water. Both here and elsewhere in the specification the non-aqueous solvent can be a mixture of non-aqueous solvents. In this case the feedstock of the drying step can be a single phase material in which both the water-soluble carrier and the water-insoluble triptan are dissolved. It is also 25 possible for this feedstock to be an emulsion, provided that both the carrier and the triptan are dissolved in the same phase. The "single-phase" method is generally believed to give a better nano-dispersion with a smaller particle size than the emulsion method. 30 It is believed that ratios of components which decrease the relative concentration of the triptan to the solvents and/or the carrier give a smaller particle size.
    WO 2008/007151 -10- PCT/GB2007/050408 Drying Spray drying is well known to those versed in the art. In the case of the present invention some care must be taken due to the presence of a volatile non-aqueous solvent in the emulsion being dried. In order to reduce the risk of explosion when a 5 flammable solvent is being used, an inert gas, for example nitrogen, can be employed as the drying medium in a so-called closed spray-drying system. The solvent can be recovered and re-used. We have found that the Buchi B-290 type laboratory spray drying apparatus is 10 suitable. It is preferable that the drying temperature should be at or above 100*C, preferably above 120"C and most preferably above 140"C. Elevated drying temperatures have been found to give smaller particles in the re-dissolved nano-disperse material. 15 Carrier Material The carrier material is water soluble, which includes the formation of structured aqueous phases as well as true ionic solution of molecularly mono-disperse species. The carrier material preferably comprises an inorganic material, surfactant, a 20 polymer or may be a mixture of two or more of these. It is envisaged that other non-polymeric, organic, water-soluble materials such as sugars can be used as the carrier. However the carrier materials specifically mentioned herein are preferred. 25 Suitable carrier materials (referred to herein as "water soluble carrier materials") include preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials. 30 Preferred polymeric carrier materials Examples of suitable water-soluble polymeric carrier materials include: (a) natural polymers (for example naturally occurring gums such as guar gum, alginate, locust bean gum or a polysaccharide such as dextran; WO 2008/007151 PCT/GB2007/050408 (b) cellulose derivatives for example xanthan gum, xyloglucan, cellulose acetate, methylcellulose, methyl-ethylcellulose, hydroxy-ethylcellulose, hydroxy-ethylmethyl-cellulose, hydroxy-propylcellulose, hydroxy propylmethylcellulose, hydroxy-propylbutylcellulose, ethylhydroxy 5 ethylcellulose, carboxy-methylcellulose and its salts (e.g. the sodium salt - SCMC), or carboxy-methylhydroxyethylcellulose and its salts (for example the sodium salt); (c) homopolymers of or copolymers prepared from two or more monomers selected from: vinyl alcohol, acrylic acid, methacrylic acid, 10 acrylamide, methacrylamide, acrylamide methylpropane sulphonates, aminoalkylacrylates, aminoalkyl-methacrylates, hydroxyethylacrylate, hydroxyethylmethylacrylate, vinyl pyrrolidone, vinyl imidazole, vinyl amines, vinyl pyridine, ethyleneglycol and other alkylene glycols, ethylene oxide and other alkylene oxides, ethyleneimine, 15 styrenesulphonates, ethyleneglycolacrylates and ethyleneglycol methacrylate; (d) cyclodextrins, for example p-cyclodextrin; and (e) mixtures thereof. 20 When the polymeric material is a copolymer it may be a statistical copolymer (heretofore also known as a random copolymer), a block copolymer, a graft copolymer or a hyperbranched copolymer. Co-monomers other than those listed above may also be included in addition to those listed if their presence does not destroy the water soluble or water dispersible nature of the resulting polymeric 25 material. Examples of suitable and preferred homopolymers include poly-vinylalcohol, poly acrylic acid, poly-methacrylic acid, poly-acrylamides (such as poly-N isopropylacrylamide), poly-methacrylamide; poly-acrylamines, poly-methyl 30 acrylamines, (such as polydimethylaminoethylmethacrylate and poly-N morpholinoethylmethacrylate), polyvinylpyrrolidone, poly-styrenesulphonate, polyvinylimidazole, polyvinylpyridine, poly-2-ethyl-oxazoline poly-ethyleneimine and ethoxylated derivatives thereof.
    WO 2008/007151 -12- PCT/GB2007/050408 Polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(2-ethyl-2-oxazaline), polyvinyl alcohol (PVA) hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC) and alginates are preferred polymeric carrier materials. 5 Preferred surfactant carrier materials Where the carrier material is a surfactant, the surfactant may be non-ionic, anionic, cationic, amphoteric or zwitterionic. 10 Examples of suitable non-ionic surfactants include ethoxylated triglycerides; fatty alcohol ethoxylates; alkylphenol ethoxylates; fatty acid ethoxylates; fatty amide ethoxylates; fatty amine ethoxylates; sorbitan alkanoates; ethylated sorbitan alkanoates; alkyl ethoxylates; PluronicsTM; alkyl polyglucosides; stearol ethoxylates; and alkyl polyglycosides. 15 Examples of suitable anionic surfactants include alkylether sulfates; alkylether carboxylates; alkylbenzene sulfonates; alkylether phosphates; dialkyl sulfosuccinates; sarcosinates; alkyl sulfonates; soaps; alkyl sulfates; alkyl carboxylates; alkyl phosphates; paraffin sulfonates; secondary n-alkane sulfonates; alpha-olefin 20 sulfonates; and isethionate sulfonates. Examples of suitable cationic surfactants include fatty amine salts; fatty diamine salts; quaternary ammonium compounds; phosphonium surfactants; sulfonium surfactants; and sulfonxonium surfactants. 25 Examples of suitable zwitterionic surfactants include N-alkyl derivatives of amino acids (such as glycine, betaine, aminopropionic acid); imidazoline surfactants; amine oxides; and amidobetaines. 30 Mixtures of surfactants may be used. In such mixtures there may be individual components which are liquid, provided that the carrier material overall, is a solid.
    WO 2008/007151 - 13 - PCT/GB2007/050408 Alkoxylated nonionics (especially the PEG/PPG PluronicTM materials), phenol ethoxylates (especially TRITONTM materials), alkyl sulphonates (especially SDS), ester surfactants (preferably sorbitan esters of the SpanTM and TweenTM types) and cationics (especially cetyltrimethylammonium bromide - CTAB) are particularly 5 preferred as surfactant carrier materials. Preferred inorganic carrier materials The carrier material can also be a water-soluble inorganic material which is neither a surfactant nor a polymer. Simple organic salts have been found suitable, particularly 10 in admixture with polymeric and/or surfactant carrier materials as described above. Suitable salts include carbonate, bicarbonates, halides, sulphates, nitrates and acetates, particularly soluble salts of sodium, potassium and magnesium. Preferred materials include sodium carbonate, sodium bicarbonate and sodium sulphate. These materials have the advantage that they are cheap and physiologically 15 acceptable. They are also relatively inert as well as compatible with many materials found in pharmaceutical products. Mixtures of carrier materials are advantageous. Preferred mixtures include combinations of surfactants and polymers, which include at least one of: 20 a) polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC), and alginates; and at least one of: b) alkoxylated nonionics (especially the PEG/PPG PluronicTM materials), phenol-ethoxylates (especially TRITONTM materials), alkyl sulphonates 25 (especially SDS), ester surfactants (preferably sorbitan esters of the SpanTM and TweenTM types) and cationics (especially cetyltrimethylammonium bromide - CTAB). The carrier material can also be a water-soluble small organic material which is 30 neither a surfactant, a polymer nor an inorganic carrier material. Simple organic sugars have been found to be suitable, particularly in admixture with a polymeric and/or surfactant carrier material as described above. Suitable small organic WO 2008/007151 -14- PCT/GB2007/050408 materials include mannitol, polydextrose, xylitol, maltitol, dextrose, dextrins, dextrans, maltodextrin and inulin, etc. Non-aqueous solvent 5 The compositions of the invention comprise a volatile, second non-aqueous solvent. This may either be miscible with the other solvents in pre-mix before drying or, together with those solvents may form an emulsion. In one alternative form of the invention a single, non-aqueous solvent is employed 10 in which can form a single phase with water in the presence of the triptan and the carrier. Preferred solvents for these embodiments are polar, protic or aprotic solvents. Generally preferred solvents have a dipole moment greater than 1 and a dielectric constant greater than 4.5. 15 Particularly preferred solvents are selected from the group consisting of haloforms (preferably dichloromethane, chloroform), lower (Cl-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitriles (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones 20 (preferably methyl ethyl ketone, acetone), and other water miscible species comprising hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Haloforms, lower alcohols, ketones and dialkylsulphoxides are the most preferred 25 solvents. In another alternative form of the invention the non-aqueous solvent is not miscible with water and forms an emulsion. 30 The non-aqueous phase of the emulsion is preferably selected from one or more from the following group of volatile organic solvents: " alkanes, preferably heptane, n-hexane, isooctane, dodecane, decane; " cyclic hydrocarbons, preferably toluene, xylene, cyclohexane; WO 2008/007151 -15- PCT/GB2007/050408 * halogenated alkanes, preferably dichloromethane, dichoroethane, trichloromethane (chloroform), fluoro-trichloromethane and tetrachloroethane; e esters, preferably ethyl acetate; e ketones, preferably 2-butanone; 5 e ethers, preferably diethyl ether; e volatile cyclic silicones, preferably either linear or cyclomethicones containing from 4 to 6 silicon units. Suitable examples include DC245 and DC345, both of which are available from Dow Corning Inc. 10 Preferred solvents include dichloromethane, chloroform, ethanol, acetone and dimethyl sulphoxide. Preferred non-aqueous solvents, whether miscible or not, have a boiling point of less than 150*C and, more preferably, have a boiling point of less than 100"C, so as 15 to facilitate drying, particularly spray-drying under practical conditions and without use of specialised equipment. Preferably they are non-flammable, or have a flash point above the temperatures encountered in the method of the invention. Preferably, the non-aqueous solvent comprises from about 10% to about 95% v/v 20 of any emulsion formed, more preferably from about 2 0% to about 80% v/v. In the single phase method the level of solvent is preferably 20-100% v/v. Particularly preferred solvents are alcohols, particularly ethanol and halogenated solvents, more preferably chlorine-containing solvents, most preferably solvents 25 selected from (di- or trichloromethane). Optional Cosurfactant In addition to the non-aqueous solvent an optional co-surfactant may be employed in the composition prior to the drying step. We have determined that the addition 30 of a relatively small quantity of a volatile cosurfactant reduced the particle diameter of the material produced. This can have a significant impact on particle volume. For example, reduction from 297 nm to 252 nm corresponds to a particle size reduction of approximately 40%. Thus, the addition of a small quantity of co-surfactant offers WO 2008/007151 -16- PCT/GB2007/050408 a simple and inexpensive method for reducing the particle size of materials according to the present invention without changing the final product formulation. Preferred co-surfactants are short chain alcohols or amine with a boiling point of 5 <220 0 C. Preferred co-surfactants are linear alcohols. Preferred co-surfactants are primary alcohols and amines. Particularly preferred co-surfactants are selected from the group consisting of the 3-6 carbon alcohols. Suitable alcohol co-surfactants include 10 n-propanol, n-butanol, n-pentanol, n-hexanol, hexylamine and mixtures thereof. Preferably the co-surfactant is present in a quantity (by volume) less than the solvent preferably the volume ratio between the solvent and the co-surfactant falls in the range 100:40 to 100:2, more preferably 100:30 to 100:5. 15 Preferred Spray-Drying Feedstocks Typical spray drying feedstocks comprise: a) a surfactant; b) at least one lower alcohol; 20 c) more than 0.1% of at least one water-insoluble triptan dissolved in the feedstock; d) a polymer; and, e) optional water. 25 Preferred spray-drying feedstocks comprise: a) at least one non-aqueous solvent selected from dichloromethane, chloroform, ethanol, acetone, and mixtures thereof; b) a surfactant selected from PEG co-polymer nonionics (especially the PEG/PPG PluroniTM materials), alkyl sulphonates (especially SDS), 30 ester surfactants (preferably sorbitan esters of the SpanTM and TweenTM types) and cationics (especially cetyltrimethylammonium bromide CTAB) and mixtures thereof; c) more than 0.1% of at least one water-insoluble triptan; WO 2008/007151 17 PCT/GB2007/050408 d) a polymer selected from Polyethylene glycol (PEG), Polyvinyl alcohol (PVA), polyvinyl-pyrrolidone (PVP), hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC) , alginates and mixtures thereof; and 5 e) optionally, water. The drying feed-stocks used in the present invention are either emulsions or solutions which preferably do not contain any solid matter and in particular preferably do not contain any undissolved triptan. 10 The level of the triptan in the composition may be up to 95% wt, up to 90%, up to 85%, up to 80%, up to 75%, up to 70%, up to 65%, up to 60%, up to 55%, up to 50%, up to 45%, up to 40%, up to 35% or up to 30%. It is particularly preferable that the level of the triptan in the composition should be such that the loading in 15 the dried composition is below 40% wt, and more preferably below 30% wt. Such compositions have the advantages of a small particle size and high effectiveness as discussed above. Water-Dispersed Form 20 On admixture of the water-soluble carrier material with water, the carrier dissolves and the water-insoluble triptan is dispersed through the water in sufficiently fine form that it behaves like a soluble material in many respects. The particle size of the water-insoluble materials in the dry product is preferably such that, on solution in water the water-insoluble materials have a particle size of less than 1 ptm as 25 determined by the Malvern method described herein. It is believed that there is no significant reduction of particle size for the triptan on dispersion of the solid form in water. By applying the present invention significant levels of "water-insoluble" materials 30 can be brought into a state which is largely equivalent to true solution. When the dry product is dissolved in water it is possible to achieve optically clear solutions comprising more than 0.1%, preferably more than 0.5% and more preferably more than 1% of the water-insoluble material.
    WO 2008/007151 - 18 - PCT/GB2007/050408 It is envisaged that the solution form will be a form suitable for administration to a patient either "as is" or following further dilution. In the alternative, the solution form of embodiments of the invention may be combined with other active materials 5 to yield a medicament suitable for use in combination therapy. Examples In order that the present invention may be further understood and carried forth into practice it is further described below with reference to non-limiting examples. 10 A range of formulations were produced based on different excipients, different active loadings, and different process conditions. The formulations include sumatriptan as an illustrative example of a triptan, but could equally have been prepared using one of the other available water insoluble triptans. 15 The excipients were chosen from hydroxypropyl cellulose (Klucel EF, Herlus), polyvinyl pyrrolidone (PVP k30, Aldrich), hydroxypropyl methyl cellulose (HPMC, Mw 10k, 5cps, Aldrich), polyethylene glycol (PEG, Mw 6,000, Fluka), Tween 80 (Aldrich), pluronic F68 (BASF), pluronic F127 (Aldrich), span 80 (Aldrich), 20 cremphor RH40 (BASF), mannitol (Aldrich), and sodium alginate (Aldrich). Details of these formulations are listed as below: Example 1: (20 wt% loadings) 25 0.40 g Sumatriptan, 1.00 g Klucel EF, 0.44 g HPMC, and 0.16 g Pluronic F68 are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before adding 60 ml distilled water. A clear solution is obtained. 30 The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 120 *C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 500 nm.
    WO 2008/007151 19 PCT/GB2007/050408 Example 2: (20 wt% loadings) 0.40 g Sumatriptan, 1.00 g Klucel EF, 0.34 g HPMC, 0.16 g Pluronic F127, and 0.10 g Tween 80 are all dispersed into 100 ml absolute ethanol. The ethanol suspension 5 is stirred intensively with a magnetic bar for about half hour before adding 60 ml distilled water. A clear solution is obtained. The solution was then spray dried with a BUCHI Mini B-290 spray dryer at 120*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 10 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of 100 to 500 nm. Two dissolution tests based on a 20 mg sumatriptan dose and an 80 mg sumatriptan 15 dose are carried out using the standard USP2 test. 50% of the 20 mg dose is expected to dissolve within less than 10 minutes and 50% of the 80mg dose within 30 minutes. 9 5 % of the 20 mg dose is expected to dissolve within less than 60 minutes and 95% of the 80 mg dose within less than 150 minutes. 20 Example 3: (20 wt% loadings) 0.40 g Sumatriptan, 1.00 g Klucel EF, and 0.60 g HPMC are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before adding 60 ml distilled water. A clear solution is obtained. 25 The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder was dispersed into 10 ml distilled water, giving a crystal clear 30 nanodispersion with a particle size of between 100 and 500 nm. Example 4: (20 wt% loadings) WO 2008/007151 -20- PCT/GB2007/050408 0.40 g Sumatriptan, 1.44 g Klucel EF, and 0.16 g PEG 6000 are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour and a clear solution is obtained. 5 The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a translucent nanodispersion with a particle size of between 300 and 800 nm. 10 Example 5: (20 wt% loadings) 0.40 g Sumatriptan, 1.00 g Klucel EF, 0.18 g HPMC, 0.16 g PEG 6000, 0.16 g Pluronic F127, and 0.10 g Tween 80 are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with magnetic bar for about half hour 15 before adding 60 ml distilled water. A clear solution is obtained. The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of 100 to 200 nm. Example 6: (20 wt% loadings) 0.40 g Sumatriptan, 1.34 g Klucel EF, 0.16 g Pluronic F127, and 0.10 g Cremphor 25 RH40 are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before adding 60 ml distilled water. A clear solution is obtained. The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C 30 with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder was dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 200 nm.
    WO 2008/007151 - 21 - PCT/GB2007/050408 Two dissolution tests based on a 20 mg sumatriptan dose and an 80 mg sumatriptan dose are carried out for formulations following the standard USP2 test. 50% of the 20 mg dose is expected to dissolve within less than 10 minutes and 50% of the 5 80mg dose within less than 5 minutes. 95% of the 20 mg dose is expected to dissolve within less than 25 minutes and 95% of the 80 mg dose within less than 90 minutes. Example 7: (20 wt% loadings) 10 0.40 g Sumatriptan, 1.18 g Klucel EF, 0.16 g Pluronic F68, 0.16 g Pluronic F127, and 0.10 g Span 80 are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before adding 10 ml distilled water. A clear solution is obtained. 15 The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 300 nm. 20 Example 8: (20 wt% loadings) 0.40 g Sumatriptan, 1.40 g Klucel EF, 0.10 g Tween 80, and 0.10 g Span 80 are all dispersed into 100 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour and a clear solution is obtained. 25 The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear 30 nanodispersion with a particle size of between 100 and 300 nm. Example 9: (30 wt% loadings) WO 2008/007151 PCT/GB2007/050408 - 22 0.30 g Sumatriptan, 0.57 g Klucel EF, 0.05 g PEG 6000, 0.05 g Pluronic F127, and 0.03 g Tween 80 are all dispersed into 50 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before adding 30 ml distilled water. A clear solution is obtained. 5 The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear 10 nanodispersion with a particle size of between 100 and 400 nm. Example 10: (30 wt% loadings) 0.30 g Sumatriptan, 0.65 g Klucel EF, 0.025 g Tween 80, and 0.025 g Span 80 are all dispersed into 50 ml absolute ethanol. The ethanol suspension is stirred intensively 15 with a magnetic bar for about half hour and a clear solution is obtained. The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 20 mg dried powder is dispersed into 10 ml distilled water, giving a translucent nanodispersion with a particle size of between 200 and 400 nm. Example 11: (20 wt% loadings) 0.20 g Sumatriptan, 0.40 g Klucel EF, 0.10 g Pluronic F127, 0.10 g Tween 80, and 25 0.20 g Mannitol are all dispersed into 50 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before added 30 ml distilled water. A clear solution is obtained. The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 140*C 30 with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 300 nm.
    WO 2008/007151 PCT/GB2007/050408 - 23 A dissolution test based on a 20 mg sumatriptan dose is carried out for formulation obtained from Example 11 following the standard USP2 test. 50% of the 20 mg dose is expected to dissolve within less than 5 minutes and 9 5 % within less than 10 5 minutes. Example 12: (20 wt% loadings) 0.20 g Sumatriptan, 0.50 g Klucel EF, 0.10 g Pluronic F127, and 0.20 g Mannitol are all dispersed into 50 ml absolute ethanol. The ethanol suspension is stirred 10 intensively with a magnetic bar for about half hour before adding 30 ml distilled water. A clear solution is obtained. The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 140 0 C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 15 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 300 nm. A dissolution test based on a 20 mg sumatriptan dose is carried out for following 20 the standard USP2 test. 95% of the 20 mg dose is expected to dissolve within less than 5 minutes. Example 13 (20 wt% loadings) 0.20 g Sumatriptan, 0.60 g Klucel EF, 0.05 g Pluronic F127, 0.05 g Tween 80, and 25 0.10 g Mannitol are all dispersed into 50 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour before adding 30 ml distilled water. A clear solution is obtained. The solution is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C 30 with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 300 nm.
    WO 2008/007151 -24- PCT/GB2007/050408 Example 14: (20 wt% loadings) 0.20 g Sumatriptan, 0.60 g Klucel EF, 0.10 g Pluronic F127, 0.025 g Tween 80, and 0.025 g Span 80 are all dispersed into 50 ml absolute ethanol. The ethanol 5 suspension is stirred intensively with a magnetic bar for about half hour and a clear ethanol solution was formed. 0.05 g Sodium alginate is dissolved into 30 ml distilled water. The ethanol solution and the aqueous solution are mixed together and a clear mixture is obtained. 10 The mixture is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 100 and 400 nm. 15 Example 15: (20 wt% loadings) 0.20 g Sumatriptan, 0.60 g Klucel EF, 0.15 g Pluronic F127 are all dispersed into 50 ml absolute ethanol. The ethanol suspension is stirred intensively with a magnetic bar for about half hour. 0.05 g Sodium alginate is dissolved into 30 ml distilled 20 water. The ethanol dispersion and the aqueous solution are mixed together and a clear mixture is obtained. The mixture is then spray dried with a BUCHI Mini B-290 spray dryer at 160*C with the liquid feed rate at 2.5 ml/min. A white free flowing powder is obtained. 25 20 mg dried powder is dispersed into 10 ml distilled water, giving a crystal clear nanodispersion with a particle size of between 200 and 400 nm. A dissolution test based on a 20 mg sumatriptan dose is carried out for the 30 formulation prepared in Example 15 following the standard USP2 test. 50% of the 20 mg dose is expected to dissolve within less than 5 minutes and 95% within less than 90 minutes.
    WO 2008/007151 -25- PCT/GB2007/050408 Example 16 This example summarises the experimental conditions used to produce three consecutive batches of spray dried Sumatriptan USP formulation (containing 40% (w/w) sumatriptan). The batches were spray dried using a Niro Mobile Minor and 5 the same spray drying conditions used for each batch. A single solution of the sumatriptan formulation was prepared and used to produce the batches, with spray drying occurring over a 2-day period. All chemicals used for spray drying studies were sourced by Iota NanoSolutions. 10 These include, for Sumatriptan Batches SMT/0706003 and SMT/0602002: * Tween 80 supplied by Croda Iota Batch E0028D " Mannitol supplied by Roquette Iota Batch E0010 " Polydextran supplied by Danisco Iota Batch E0025 " Lutrol F127 supplied by BASF Iota Batch E0014 15 e HPMC supplied by Colorcon Iota Batch E0017 " Ethanol (Absolute) supplied in bulk by VWR Preparation of a sumatriptan solution for spray drying Day 1: 20 The following quantities of powder were weighed out (to within 0.01 g): 19.9 g Sumatriptan Batch SMT/0706003 (required amount was 20 g). The sumatriptan was added to 1.0 L ethanol and left to stir overnight at room temperature in a capped bottle. 25 Day 2: A further 1.5 L of ethanol was added to the suspension and stirred for 1 hour to fully dissolve the sumatriptan (total volume of ethanol was 2.5 L). A pale yellow solution was produced. 30 18 g HPMC was then added to the ethanolic sumatriptan solution and stirred briskly for 1 hour to produce an even suspension.
    WO 2008/007151 - 26 - PCT/GB2007/050408 The following aqueous solution was prepared separately by adding the following solutes to 2.5 L of de-ionised water and stirring for 1 hour: 3 g Mannitol, 3 g Polydextran, 3 g Lutrol F127, and 3 g Tween 80. The aqueous solution was then added to the sumatriptan/HPMC suspension and stirred for 30 mins. The resulting 5 solution became "clear" but then became "cloudy" as the final amounts of aqueous solution were added. Total solids content at this stage was 50 g solids in 5.0 L 50% (v/v) ethanol/water solution (i.e. 1% (w/v)) To return to a "clear" solution a decision was made to adjust the solute 10 concentrations and solvent concentrations such that the solids content remained at ~ 1% (w/v) but that the ethanol concentration was raised to 60% (v/v). The following quantities of powder were weighed out (to within 0.01 g): 10 g Sumatriptan Batch SMT/0602002. The sumatriptan was added to 1.25 L ethanol 15 and left to stir at room temperature for 2 hours. When the sumatriptan had dissolved, 9 g of HPMC was added and stirred for 1 hour to create a homogeneous suspension. Additional solutes were added to the existing 5 L volume of sumatriptan solution and the solution stirred for 30 mins, namely: 1.5 g Mannitol, 1.5 g Polydextran, 1.5 g Lutrol F127 and 1.5 g Tween 80. The aqueous solution was 20 then added to the 1.25 L of ethanolic Sumatriptan/HPMC suspension and stirred for 30 mins. The resulting solution was clear, pale yellow. The final solution contained 75 g solids in 6.25 L of 60 %(v/v) ethanol/water i.e. 1.2% (w/v) solids. 25 The process for manufacturing the sumatriptan spray solution is summarised in the flowchart shown in Figure 1. Spray drying process 30 A 2 L volume of the sumatriptan solution was spray dried using a Niro Mobile Minor fitted with a 2-fluid nozzle. The liquid feed was provided by a gear pump calibrated to provide a flow of 25 ml/minute. The following spray drying conditions were used: WO 2008/007151 -27 - PCT/GB2007/050408 Inlet temperature 1 00*C Outlet temperature (start) 57 0 C Liquid feed rate 25 ml/min Atomisation pressure 0.5 bar 5 After all of the solution had been atomised, drying was halted and the spray dried powder recovered (Batch Number INS089-UT04). The spray dryer was then cleaned and dried prior to further use. 10 A 2 L volume of the sumatriptan solution was spray dried using a Niro Mobile Minor fitted with a 2-fluid nozzle. The liquid feed was provided by a gear pump calibrated to provide a flow of 25 ml/minute. The following spray drying conditions were used: Inlet temperature 100 0 C 15 Outlet temperature (start) 59 0 C Liquid feed rate 25 ml/min Atomisation pressure 0.5 bar After all of the solution had been atomised, drying was halted and the spray dried 20 powder recovered (Batch Number INS089-UT05). The spray dryer was then cleaned and dried prior to further use. A 2 L volume of the sumatriptan solution was spray dried using a Niro Mobile Minor fitted with a 2-fluid nozzle. The liquid feed was provided by a gear pump 25 calibrated to provide a flow of 25 ml/minute. The following spray drying conditions were used: Inlet temperature 100*C Outlet temperature (start) 58 0 C Liquid feed rate 25 ml/min 30 Atomisation pressure 0.5 bar WO 2008/007151 - 28 - PCT/GB2007/050408 After all of the solution had been atomised, drying was halted and the spray dried powder recovered (Batch Number INS089-UT06). The recoveries obtained are shown in Table 1. Each spray drying run used 2.0 L of 5 a 1.2% (w/v) solution i.e. 24 g spray dried. Table 1 - Recovery of Spray Dried Powders Batch Number Quantity of Material Recovered (% of starting material) INS089-UT04 12.
    3 g (51%) INS089-UT05 15.
    3 g (64%) INS089-UT06 1 6
    .
    4 g (68%) Size analysis of the three spray dried batches were carried out using a Sympatec 10 Laser Sizer, fitted with a Rodos air dispenser. Powders dispersed at 5.0 bar. Figure 2 is a graph showing the size analysis of Sumatriptan Batch INS089-UT04, wherein: x 10 = 2.81 jim X5= 11.67 jim x 9 o = 35.99 4m 15 SMD = 5.79 jim VMD = 16.98 jim x 16 4.17 jim X= 28.41 pm x 99 = 96.35 pim Sv 1.04 m 2 /cm 3 Sm 7681.35 cm 2 /g Figure 3 is a graph showing the size analysis of Sumatriptan Batch INS089-UT05, 20 wherein: x 1 0 = 2.51 pm X50 = 9.38 jim x= 27.39 4m SMD = 5.16 jim VMD = 12.79 4m X= 3.67 pm x 84 = 21.73 4m x 99 56.73 jim Sv =1.16 m 2 /cm 3 Sm = 8619.08 cm 2 /g 25 Figure 4 is a graph showing the size analysis of Sumatriptan Batch INS089-UT06, wherein:
    X
    1 0 = 2.42 jm X= 8.90 jm X 90 = 26.09 4m SMD = 5.01 jim VMD = 12.29 jim WO 2008/007151 -29- PCT/GB2007/050408 x,6= 3.52 pm x 84 = 20.55 pm x,,= 57.62 ptm Sv = 1.20 m 2 /cm 3 Sm = 8875.92 cm 2 /g Figure 5 is a graph showing the size analysis of of Sumatriptan Batches INS089 5 UT04, INS089-UT05 and INS089-UT06. Example 17 The following materials were used as purchased, without further purification: * 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide 10 (Sumatriptan, 98%, MW 295.402 g/mol, supplied by PharmaKodex) " Hydroxypropyl methyl cellulose (HPMC, Mw 10,000, Aldrich) * Polyvinylpyrrolidone K30 (PVP, Mw 45,000, Aldrich) e Maltitol (MW 344.32 g/mol, Fluka) " Polydextrose (Litessse@ II, Danisco) 15 * Pluronic F-127 (Aldrich) " Tween 80 (MW 1309.68 g/mol, Aldrich) Sumatriptan and the excipients were dissolved into water/ethanol co-solvent and the resulting solution was then spray dried on a Buchi B-290 Mini Spray Dryer. 20 The spray drying was conducted with an inlet temperature of 100*C and a pump rate of 2.5 ml/min. The make-up of each batch is set out in Table 2. Table 2 Batch Suma- HPMC PVP Poly- Maltitol Pluromc Tween Water No. triptan (wt/o) (wt/o) dextrose (wt/o) F-127 80 :EtOH (wt%/) (wt%/) (wt%/) (wt%/.) 39 20 24 24 8 8 8 8 1:1.6 42 40 18 18 6 6 6 6 1:1.2 54 40 36 - 6 6 6 6 1:1 55 40 - 36 6 6 6 6 1:1 58 40 42 - 6 6 - 6 1:1 60 40 40 - 6 6 - 8 1:1 25 In order to measure the sumatriptan particle size distribution (PSD), a 25 mg sample of the spray dried sumatriptan batches were dissolved into 26 ml distilled WO 2008/007151 - 30 - PCT/GB2007/050408 water with stirring (vortex) before measurements were taken using Malvern Nano-S particle sizer. The dispersions were corrected for viscosity. To study the dissolution characterization, a 50 mg sample (equivalent to 20 mg 5 sumatriptan) of the spray dried batches was dissolved into 1000 ml of distilled water at 37*C with overhead paddle stirring at 50 rpm. Aliquots of each solution were taken at 5, 10, and 15 minutes. The dispersions were then diluted with 0.1 M HCl solution for UV characterization. The dissolution is expressed as a percentage of the initial sumatriptan concentration that has dissolved after specific time intervals, for 10 each formulation. Table 3 Batch % Solids in PSD Dissolution In H 2 0 Dissoluton in H20 No. solution (nm) (5 min) (10 min) 39 1.5% 354 89 100 42 0.9% 306 98 100 54 0.8% 414 91 101 55 0.8% 598 99 99 58 0.8% 1030 76 99 60 0.8% 492 97 98 A UV calibration curve was also obtained by dissolving different amounts of 15 sumatriptan into 0.1 M HC1 solution. Figures 6 and 7 show the X-ray powder diffraction results. These show that the sumatriptan nano-particle material produced is in crystalline form and not amorphous form and it is believed to be predominantly or entirely the same 20 crystalline form as the starting material.
    权利要求:
    Claims (21)
    [1] 1. A process for the production of a composition comprising a water-insoluble triptan which comprises the steps of: 5 a) providing a mixture comprising: i) a water-insoluble triptan, ii) a water soluble carrier, and iii) a solvent for each of the triptan and the carrier; and b) spray-drying the mixture to remove the or each solvent and obtain a 10 substantially solvent-free nano-dispersion of the triptan in the carrier.
    [2] 2. A process according to claim 1, which comprises the steps of: a) providing an emulsion comprising: i) a solution of the triptan in a water-immiscible solvent for the 15 same, and ii) an aqueous solution of the carrier; and b) spray-drying the emulsion to remove water and the water-immiscible solvent to obtain a substantially solvent-free nano-dispersion of the triptan in the carrier. 20
    [3] 3. A process according to claim 1, which comprises the steps of: a) providing a single phase mixture comprising: i) at least one non-aqueous solvent, ii) optionally, water, 25 iii) a water-soluble carrier material soluble in the mixture of (i) and (ii), and iv) a water-insoluble triptan which is soluble in the mixture of (i) and (ii); and b) spray-drying the solution to remove water and the water miscible 30 solvent to obtain a substantially solvent-free nano-dispersion of the triptan in the carrier. WO 2008/007151 -32- PCT/GB2007/050408
    [4] 4. A process according to any of claims 1-3, wherein the spray drying process is conducted at a temperature at or above 120*C.
    [5] 5. A process according to any of claims 1-4, in which the carrier material 5 includes a polymer and/or a surfactant.
    [6] 6. A process according to claim 5, wherein the carrier material includes at least one of polyethylene glycol, polyvinylpyrrolidone, poly(2-ethyl-2-oxazaline), polyvinyl alcohol, hydroxypropyl cellulose and hydroxypropyl-methyl cellulose and 10 alginate.
    [7] 7. A process according to claim 5, wherein the carrier material includes at least one of alkoxylated non-ionic surfactant, ether sulphate surfactant, cationic surfactant or ester surfactant. 15
    [8] 8. A process according to any one of claims 1-7, wherein the non-aqueous solvent includes at least one of dichloromethane, chloroform, ethanol, acetone and dimethyl sulphoxide. 20
    [9] 9. A process according to any one of the preceding claims, wherein the water insoluble triptan is sumatriptan, rizatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan or almotriptan.
    [10] 10. A process for the preparation of a medicament for use in the treatment 25 migraine or headache, which comprises the step of preparing a composition by a process according to any one of claims 1-9.
    [11] 11. A composition comprising a water-insoluble triptan and a water soluble carrier which comprises triptan particles with an average particle size of between 30 100 and 1500 nm dispersed in the carrier.
    [12] 12. A composition according to claim 11, wherein the composition is obtained or obtainable by the process of any one of claims 1-9. WO 2008/007151 -33- PCT/GB2007/050408
    [13] 13. A composition according to claim 11 or 12, wherein the average patticle size of the triptan particles is between 200 and 1000 nm, 400 and 1000 nm or 500 and 800 nm. 5
    [14] 14. A composition according to any one of claims 11-13, wherein the triptan particles are substantially crystalline.
    [15] 15. A composition according to any one of claims 11-14, wherein the triptan 10 particles retain the crystallinity of the original triptan material used to prepare the composition.
    [16] 16. A composition according to any one of claims 11-15, wherein the triptan particles are substantially free of amorphous material. 15
    [17] 17. A composition according to any one of claims 11-16, further comprising one or more further therapeutically active agent.
    [18] 18. A composition according to claim 17, wherein the composition comprises an 20 analgesic agent, such as an NSAID or paracetamol.
    [19] 19. A composition according to claim 17 or 18, wherein the composition comprises an anti-nausea agent, such as diphenhydramine or ondansetron. 25
    [20] 20. A composition according to any one of claims 11-19, for use in treating migraine and/or headache.
    [21] 21. A method of treating migraine and/or headache, comprising adminsitering to a patient a therapeutically effective amount of a composition according to any one 30 of claims 11-19.
    类似技术:
    公开号 | 公开日 | 专利标题
    US20100008995A1|2010-01-14|Processes for preparing pharmaceutical compositions
    US20110217381A1|2011-09-08|Pharmaceutical compositions
    EP2046296A2|2009-04-15|Processes for preparing pharmaceutical compositions
    EP2046295A1|2009-04-15|Preparation of pharmaceutical compositions
    EP2046297A2|2009-04-15|Preparation of pharmaceutical formulations
    同族专利:
    公开号 | 公开日
    EP2040680A2|2009-04-01|
    JP2009542793A|2009-12-03|
    AU2007274039A1|2008-01-17|
    JP2009542794A|2009-12-03|
    CN102671585A|2012-09-19|
    CN101516341A|2009-08-26|
    WO2008006713A3|2008-07-31|
    ES2752460T3|2020-04-06|
    EP2387992A1|2011-11-23|
    US20100068282A1|2010-03-18|
    WO2008006716A3|2008-03-13|
    BRPI0714177A2|2011-05-03|
    AU2007274041A1|2008-01-17|
    IL195911D0|2009-09-01|
    WO2008007151A2|2008-01-17|
    MX2009000309A|2009-01-26|
    CN101489534A|2009-07-22|
    CN101489535A|2009-07-22|
    US20100015233A1|2010-01-21|
    AU2007271831B2|2010-11-18|
    US8821932B2|2014-09-02|
    US20090175953A1|2009-07-09|
    CA2657548A1|2008-01-17|
    WO2008007151A3|2008-03-06|
    WO2008006712A2|2008-01-17|
    JP2009542760A|2009-12-03|
    JP2010202665A|2010-09-16|
    CA2659666A1|2008-01-17|
    AR061990A1|2008-08-10|
    AU2007271829A1|2008-01-17|
    US8945626B2|2015-02-03|
    JP2009542761A|2009-12-03|
    AU2007271828B2|2010-12-02|
    EP2269581A1|2011-01-05|
    CA2656233A1|2008-01-17|
    EP2040680B1|2019-08-07|
    CL2010000516A1|2010-10-15|
    BRPI0714230A2|2013-01-15|
    US9060937B2|2015-06-23|
    AP2008004713A0|2008-12-31|
    EP2040681A2|2009-04-01|
    WO2008006715A3|2008-05-08|
    CL2007002031A1|2008-01-18|
    CN101489531A|2009-07-22|
    ZA200900027B|2010-04-28|
    BRPI0714351A2|2013-03-19|
    EP2040677B1|2019-05-08|
    AU2007271831A1|2008-01-17|
    CN101516342A|2009-08-26|
    ZA200900031B|2010-04-28|
    IL195933D0|2009-09-01|
    US7691873B2|2010-04-06|
    US20120134940A1|2012-05-31|
    WO2008006713A2|2008-01-17|
    US20120135058A1|2012-05-31|
    JP2009542795A|2009-12-03|
    CA2656217A1|2008-01-17|
    CN101849911A|2010-10-06|
    AR061992A1|2008-08-10|
    WO2008006715A2|2008-01-17|
    CN102631874A|2012-08-15|
    AU2007271827B2|2010-10-14|
    EP2040677A2|2009-04-01|
    EP2040681B1|2017-08-09|
    JP2009542764A|2009-12-03|
    AU2007271829B2|2011-10-27|
    US20090325995A1|2009-12-31|
    BRPI0714176A2|2012-12-25|
    ZA200900029B|2010-04-28|
    EP2386292A1|2011-11-16|
    ES2741124T3|2020-02-10|
    CA2656223A1|2008-01-17|
    ZA200900347B|2010-04-28|
    US20100008995A1|2010-01-14|
    BRPI0722376A2|2012-05-22|
    US20100015229A1|2010-01-21|
    AU2010201900A1|2010-06-03|
    AU2007271828A1|2008-01-17|
    CN101489532A|2009-07-22|
    ZA200900028B|2010-04-28|
    WO2008006714A2|2008-01-17|
    AR077195A2|2011-08-10|
    WO2008006712A3|2009-02-26|
    CL2007002032A1|2008-01-18|
    WO2008007150A1|2008-01-17|
    WO2008007152A3|2008-03-06|
    MX2009000307A|2009-01-26|
    ZA200900030B|2010-04-28|
    WO2008006714A3|2008-02-21|
    EP2040679A2|2009-04-01|
    US20090304806A1|2009-12-10|
    CA2657586A1|2008-01-17|
    CA2656229A1|2008-01-17|
    TW200812694A|2008-03-16|
    IL195933A|2013-06-27|
    EP2040678A2|2009-04-01|
    CN101489533A|2009-07-22|
    AU2007271830B2|2010-11-11|
    CN101516340A|2009-08-26|
    BRPI0714353A2|2013-05-07|
    AU2007271827A1|2008-01-17|
    BRPI0714179A2|2012-12-25|
    JP2009542762A|2009-12-03|
    AU2007271830A1|2008-01-17|
    CA2656229C|2014-05-27|
    WO2008006716A2|2008-01-17|
    JP2009542763A|2009-12-03|
    ZA200900345B|2010-05-26|
    US20090239749A1|2009-09-24|
    CA2657582A1|2008-01-17|
    BRPI0714352A2|2013-03-19|
    CL2007002030A1|2008-01-18|
    WO2008007152A2|2008-01-17|
    AR061991A1|2008-08-10|
    GB0613925D0|2006-08-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB501835A|1936-05-29|1939-03-02|Siemens Ag|Process and apparatus for reducing the power required for the mechanical treatment of movable masses|
    GB1305024A|1969-07-10|1973-01-31|||
    GB1554662A|1976-05-05|1979-10-24|Inverni Della Beffa Spa|Polyhydroxyphenylchromanones|
    US4230687A|1978-05-30|1980-10-28|Griffith Laboratories U.S.A., Inc.|Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices|
    DE3439482C2|1984-10-27|1993-06-09|Roehm Gmbh, 6100 Darmstadt, De||
    US4830858A|1985-02-11|1989-05-16|E. R. Squibb & Sons, Inc.|Spray-drying method for preparing liposomes and products produced thereby|
    US5160530A|1989-01-24|1992-11-03|Griffin Corporation|Microencapsulated polymorphic agriculturally active material|
    GB8918807D0|1989-08-17|1989-09-27|Shell Int Research|A solid pesticidal formulation,a process for its preparation and the use thereof|
    JP3067810B2|1990-12-21|2000-07-24|中外製薬株式会社|Method for producing dry powder of O / W emulsion for oral administration|
    GB9304294D0|1993-03-03|1993-04-21|Zeneca Ltd|Herbicidal compositions|
    DE4329446A1|1993-09-01|1995-03-02|Basf Ag|Process for the production of finely divided color or active substance preparations|
    US5858398A|1994-11-03|1999-01-12|Isomed Inc.|Microparticular pharmaceutical compositions|
    TW318777B|1995-06-29|1997-11-01|Novartis Ag||
    WO1997013503A1|1995-10-13|1997-04-17|The Penn State Research Foundation|Synthesis of drug nanoparticles by spray drying|
    GB9606188D0|1996-03-23|1996-05-29|Danbiosyst Uk|Pollysaccharide microspheres for the pulmonary delivery of drugs|
    US5858409A|1996-04-17|1999-01-12|Fmc Corporation|Hydrolyzed cellulose granulations for pharmaceuticals|
    JP4183279B2|1997-04-15|2008-11-19|アールピーシェーラーテクノロジーズインコーポレーテッド|Hydrolyzed cellulose granules for pharmaceutical use|
    US5985248A|1996-12-31|1999-11-16|Inhale Therapeutic Systems|Processes for spray drying solutions of hydrophobic drugs and compositions thereof|
    CN1138536C|1998-03-05|2004-02-18|日本新药株式会社|Fat emulsions for inhalational administration|
    JPH11322587A|1998-05-18|1999-11-24|Sumitomo Chem Co Ltd|Microcapsulation of physiologically active substance solid at room temperature and microcapsule composition obtained thereby|
    JP2002534371A|1999-01-06|2002-10-15|コリアリサーチインスティテュートオブケミカルテクノロジー|Method for producing pharmaceutically active ingredient containing water-insoluble drug and pharmaceutical composition for oral administration containing the same|
    DE60039379D1|1999-02-10|2008-08-21|Pfizer Prod Inc|Pharmaceutical solid dispersions|
    GB9904012D0|1999-02-22|1999-04-14|Zeneca Ltd|Agrochemical formulation|
    US7919119B2|1999-05-27|2011-04-05|Acusphere, Inc.|Porous drug matrices and methods of manufacture thereof|
    US6610317B2|1999-05-27|2003-08-26|Acusphere, Inc.|Porous paclitaxel matrices and methods of manufacture thereof|
    US6395300B1|1999-05-27|2002-05-28|Acusphere, Inc.|Porous drug matrices and methods of manufacture thereof|
    ES2250141T5|1999-05-27|2009-11-05|Acusphere, Inc.|POROUS MATRICES OF DRUGS AND METHODS TO MANUFACTURE THEM.|
    GB9915231D0|1999-06-29|1999-09-01|Pfizer Ltd|Pharmaceutical complex|
    GB9920148D0|1999-08-25|1999-10-27|Smithkline Beecham Plc|Novel composition|
    WO2001039836A1|1999-12-01|2001-06-07|Natco Pharma Limited|A rapid acting freeze dired oral pharmaceutical composition for treating migraine|
    KR100694667B1|1999-12-08|2007-03-14|동아제약주식회사|Antifungal compositions containing itraconazole with both improved bioavailability and narrow intra- and inter-individual variation of its absorption|
    US6207674B1|1999-12-22|2001-03-27|Richard A. Smith|Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants|
    US6932963B2|2000-06-23|2005-08-23|Nicholas V. Perricone|Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines|
    AU7488001A|2000-05-22|2001-12-03|Verion Inc|Method for increasing the compressibility of poorly binding powder materials|
    IT1318618B1|2000-07-10|2003-08-27|A C R Applied Coating Res S A|QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS.|
    KR100807650B1|2000-07-24|2008-02-28|오노 야꾸힝 고교 가부시키가이샤|FREEZE-DRIED PREPARATION OF N-[o-p-PIVALOYLOXYBENZENESULFONYLAMINOBENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME|
    DE10036871A1|2000-07-28|2002-02-14|Pharmasol Gmbh|Dispersions for the formulation of poorly or poorly soluble active ingredients|
    DE60129573T2|2000-09-20|2008-04-17|Jagotec Ag|PROCESS FOR SPRAY DRYING OF COMPOSITIONS CONTAINING FENOFIBRATE|
    US6756062B2|2000-11-03|2004-06-29|Board Of Regents University Of Texas System|Preparation of drug particles using evaporation precipitation into aqueous solutions|
    US8067032B2|2000-12-22|2011-11-29|Baxter International Inc.|Method for preparing submicron particles of antineoplastic agents|
    WO2002060411A2|2001-01-30|2002-08-08|Board Of Regents University Of Texas System|Process for production of nanoparticles and microparticles by spray freezing into liquid|
    US6355675B1|2001-05-15|2002-03-12|Isp Investments Inc.|Emulsifiable concentrate of a water-insoluble fungicide|
    AU2002305758B2|2001-06-01|2006-09-07|Nuvo Pharmaceuticals Designated Activity Company|Pharmaceutical compositions for the coordinated delivery of NSAIDs|
    DE60237602D1|2001-06-22|2010-10-21|Bend Res Inc|PHARMACEUTICAL COMPOSITION CONTAINING HEAVY SOLUBLE AND ACIDIC TOXIC SUBSTANCES AND NEUTRALIZED ANIONIC POLYMERS|
    KR100425226B1|2001-07-03|2004-03-30|주식회사 팜트리|Compositions and preparation methods for bioavailable oral aceclofenac dosage forms|
    EP1420582B1|2001-08-21|2012-03-21|Sony Corporation|Information processing system; information processing apparatus; and method|
    CA2461349C|2001-09-26|2011-11-29|Baxter International Inc.|Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal|
    US20060003012A9|2001-09-26|2006-01-05|Sean Brynjelsen|Preparation of submicron solid particle suspensions by sonication of multiphase systems|
    DE10151392A1|2001-10-18|2003-05-08|Bayer Cropscience Ag|Powdery solid formulations|
    WO2003039249A2|2001-11-07|2003-05-15|Basf Aktiengesellschaft|Nanoparticles comprising a crop protection agent|
    JP4235109B2|2001-11-07|2009-03-11|ビーエーエスエフソシエタス・ヨーロピア|Crop protection solid formulation containing sinidone-ethyl and corresponding dispersion|
    ES2878403T3|2002-02-01|2021-11-18|Bend Res Inc|Method for preparing spray dried homogeneous solid amorphous drug dispersions using modified spray drying apparatus|
    CA2473991C|2002-02-01|2009-09-15|Pfizer Products Inc.|Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor|
    US6780324B2|2002-03-18|2004-08-24|Labopharm, Inc.|Preparation of sterile stabilized nanodispersions|
    US20040028505A1|2002-06-07|2004-02-12|Bilbrey Robert A.|Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms|
    JP4831965B2|2002-06-10|2011-12-07|エランファーマインターナショナル，リミティド|Nanoparticle formulations comprising HMG-CoA reductase inhibitor derivatives , novel combinations thereof, and the manufacture of these pharmaceutical compositions|
    US20030017208A1|2002-07-19|2003-01-23|Francis Ignatious|Electrospun pharmaceutical compositions|
    DE10244681A1|2002-09-24|2004-04-08|Boehringer Ingelheim International Gmbh|New solid telmisartan-containing pharmaceutical formulations and their preparation|
    AU2003268380A1|2002-10-04|2004-05-04|Elan Pharma International Limited|Gamma irradiation of solid nanoparticulate active agents|
    CN1176649C|2002-10-16|2004-11-24|上海医药工业研究院|Inhalant of Shumaputan dry-powder and its preparation method|
    US20040220081A1|2002-10-30|2004-11-04|Spherics, Inc.|Nanoparticulate bioactive agents|
    MXPA05006954A|2002-12-26|2005-09-22|Pozen Inc|Multilayer Dosage Forms Containing NSAIDs and Triptans.|
    EP1585542B1|2002-12-27|2012-06-13|Novartis Vaccines and Diagnostics, Inc.|Immunogenic compositions containing phospholipid|
    CA2513729A1|2003-01-21|2004-08-05|Ranbaxy Laboratories Limited|Co-precipitated amorphous losartan and dosage forms comprising the same|
    US20040197301A1|2003-02-18|2004-10-07|Zhong Zhao|Hybrid polymers and methods of making the same|
    CA2514875A1|2003-02-19|2004-09-02|Biovail Laboratories International Srl|Rapid absorption selective 5-ht agonist formulations|
    WO2004075921A1|2003-02-26|2004-09-10|Vrije Universiteit Brussel|Inclusion complex of artemisinin or derivates thereof with cyclodextrins|
    US20040259899A1|2003-04-08|2004-12-23|Sanghvi Suketu P.|Combination therapy for constipation|
    US20040247624A1|2003-06-05|2004-12-09|Unger Evan Charles|Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility|
    CA2465565A1|2003-06-12|2004-12-12|Warner-Lambert Company Llc|Pharmaceutical compositions of atorvastatin|
    WO2005014043A1|2003-07-16|2005-02-17|Boehringer Ingelheim International Gmbh|Chlorthalidone combinations|
    US7687167B2|2003-07-18|2010-03-30|Panasonic Corporation|Power supply unit|
    CL2004001884A1|2003-08-04|2005-06-03|Pfizer Prod Inc|DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.|
    DE10338403A1|2003-08-18|2005-03-17|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- piperazine, process for its preparation and its use as inhalant|
    DE10351004A1|2003-10-30|2005-05-25|Basf Ag|Aqueous nanodispersion-forming formulations of active agents, especially plant protectants such as fungicides, comprise random copolymer of unsaturated sulfonic acid|
    DE10351087A1|2003-10-31|2005-05-25|Bayer Technology Services Gmbh|Solid active ingredient formulation|
    KR100603974B1|2003-12-05|2006-07-25|김갑식|Method for preparing nano-scale or amorphous particle using solid fat as a solvent|
    CA2551254A1|2003-12-31|2005-07-21|Pfizer Products Inc.|Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers|
    KR100629771B1|2004-01-27|2006-09-28|씨제이 주식회사|Process for preparing oltipraz with diminished crystalline state or amorphous state|
    IL160095D0|2004-01-28|2004-06-20|Yissum Res Dev Co|Formulations for poorly soluble drugs|
    JP2005298347A|2004-04-06|2005-10-27|Yoshiaki Kawashima|Inhalation preparation and method for producing the same|
    KR100598326B1|2004-04-10|2006-07-10|한미약품 주식회사|EXTENDED RELEASE ORAL FORMULATION OF HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF|
    JP2007534328A|2004-04-28|2007-11-29|ユニリーバー・ナームローゼ・ベンノートシヤープ|Edible oils containing statins|
    WO2005117834A1|2004-05-27|2005-12-15|Janssen Pharmaceutica N.V.|Solid dispersions of a basic drug compound and a polymer containing acidic groups|
    MXPA06010084A|2004-06-01|2007-03-01|Teva Gyogyszergyar Zartkoruen|Process for preparation of amorphous form of a drug.|
    DE102004031298A1|2004-06-28|2006-01-12|Basf Ag|Aqueous dispersions of poorly water-soluble or water-insoluble active ingredients and dry powders prepared therefrom containing at least one polymer containing polyether groups as protective colloid|
    KR20070057901A|2004-10-01|2007-06-07|에자이 알앤드디 매니지먼트 가부시키가이샤|Composition containing fine particles and process for producing the same|
    US20060105038A1|2004-11-12|2006-05-18|Eurand Pharmaceuticals Limited|Taste-masked pharmaceutical compositions prepared by coacervation|
    JP2008526855A|2005-01-06|2008-07-24|エランファーマインターナショナルリミテッド|Nanoparticulate candesartan formulation|
    GB0501835D0|2005-01-28|2005-03-09|Unilever Plc|Improvements relating to spray dried compositions|
    GB0613925D0|2006-07-13|2006-08-23|Unilever Plc|Improvements relating to nanodispersions|
    US20080152717A1|2006-12-14|2008-06-26|Isp Investments, Inc.|Amorphous valsartan and the production thereof|GB0501833D0|2005-01-28|2005-03-09|Unilever Plc|Carrier liquids and methods of production thereof|
    US20090130212A1|2006-05-15|2009-05-21|Physical Pharmaceutica, Llc|Composition and improved method for preparation of small particles|
    GB0613925D0|2006-07-13|2006-08-23|Unilever Plc|Improvements relating to nanodispersions|
    WO2008022651A1|2006-08-21|2008-02-28|Antoine Turzi|Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells|
    AR063704A1|2006-09-14|2009-02-11|Makhteshim Chem Works Ltd|PESTICIDE NANOPARTICLES OBTAINED OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS|
    US8653066B2|2006-10-09|2014-02-18|Charleston Laboratories, Inc.|Pharmaceutical compositions|
    WO2009081283A2|2007-06-18|2009-07-02|Combino Pharm, S.L.|Aqueous formulations of acetaminophen for injection|
    WO2009047634A2|2007-06-18|2009-04-16|Combino Pharm, S.L.|Aqueous formulations of acetaminophen for injection|
    EP2601935A1|2007-09-25|2013-06-12|Solubest Ltd.|Compositions comprising lipophilic active compounds and method for their preparation|
    US8124126B2|2008-01-09|2012-02-28|Charleston Laboratories, Inc.|Pharmaceutical compositions|
    TR200800634A2|2008-01-30|2009-02-23|Takka Sevgi̇|Fluvastatin tablet for extended release.|
    US8372432B2|2008-03-11|2013-02-12|Depomed, Inc.|Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic|
    US8377453B2|2008-03-11|2013-02-19|Depomed, Inc.|Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic|
    CA2730199C|2008-07-11|2013-07-30|Nippon Soda Co., Ltd.|Method of manufacture of sustained-release formulation composition|
    GB0814953D0|2008-08-18|2008-09-24|Unilever Plc|Improvements relating to nanodisperse compositions|
    AU2009295586B2|2008-09-25|2014-01-09|Vive Nano, Inc.|Methods to produce polymer nanoparticles and formulations of active ingredients|
    FR2938433B1|2008-11-19|2011-09-09|Francois Fauran|PHARMACEUTICAL COMPOSITIONS USING INULIN AS A GRANULATING EXCIPIENT|
    EP2373464B1|2008-12-12|2019-10-23|TimTechChem International Limited|Compositions for the treatment of timber and other wood substrates|
    EP2243477A1|2009-04-22|2010-10-27|Fresenius Kabi Deutschland GmbH|Paracetamol for parenteral application|
    CN102458373A|2009-05-27|2012-05-16|株式会社三养生物制药|Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same|
    HU0900376A2|2009-06-19|2011-01-28|Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag|Nanoparticulate candesartan cilexetil composition|
    HU0900384A2|2009-06-19|2011-01-28|Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag|Nanoparticulate olmesartan medoxomil compositions|
    EP2446879B1|2009-06-25|2014-02-12|Jin Yang Pharm. Co., Ltd.|Pharmaceutical composition containing carboxylosartan and a production method therefor|
    WO2011006012A1|2009-07-08|2011-01-13|Charleston Laboratories Inc.|Pharmaceutical compositions|
    NZ598922A|2009-08-31|2014-03-28|Depomed Inc|Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen|
    JP5498769B2|2009-12-04|2014-05-21|花王株式会社|Method for producing lipid-soluble drug-encapsulating nanoparticles|
    US8597681B2|2009-12-22|2013-12-03|Mallinckrodt Llc|Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans|
    US9198861B2|2009-12-22|2015-12-01|Mallinckrodt Llc|Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans|
    EP2536396B1|2010-02-16|2016-08-10|KRKA, D.D., Novo Mesto|Process for the preparation of oral solid dosage forms comprising valsartan|
    US20130028976A1|2010-03-29|2013-01-31|Firmenich Sa|Spray-dried crystalline active ingredient|
    GB201006038D0|2010-04-12|2010-05-26|Unilever Plc|Improvements relating to antiviral compositions|
    EP2600713B1|2010-08-05|2015-12-16|Dow AgroSciences, LLC|Pesticide compositions of meso-sized particles with enhanced activity|
    CN103249406A|2010-10-05|2013-08-14|阿尔塔纳米产品有限公司|Processes for preparing improved compositions|
    US8877221B2|2010-10-27|2014-11-04|Warsaw Orthopedic, Inc.|Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same|
    US9107983B2|2010-10-27|2015-08-18|Warsaw Orthopedic, Inc.|Osteoconductive matrices comprising statins|
    WO2012082765A2|2010-12-16|2012-06-21|The United State Of America. As Represented By The Secretary Department Of Health And Human Services|Methods for decreasing body weight and treating diabetes|
    EP2696869B1|2011-04-12|2017-08-23|Rigel Pharmaceuticals, Inc.|Methods for inhibiting allograft rejection|
    US8858963B1|2011-05-17|2014-10-14|Mallinckrodt Llc|Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia|
    US8741885B1|2011-05-17|2014-06-03|Mallinckrodt Llc|Gastric retentive extended release pharmaceutical compositions|
    US8658631B1|2011-05-17|2014-02-25|Mallinckrodt Llc|Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia|
    WO2012170417A2|2011-06-06|2012-12-13|Warsaw Orthopedic, Inc.|Methods and compositions to enhance bone growth comprising a statin|
    JP2013001771A|2011-06-14|2013-01-07|Neos Co Ltd|Liquid mold control detergent composition|
    RU2469536C1|2011-06-16|2012-12-20|Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан"|Fungicidal agent and method of its production|
    EP2723452A2|2011-06-22|2014-04-30|Vyome Biosciences Pvt Ltd|Conjugate-based antifungal and antibacterial prodrugs|
    MX2014002087A|2011-08-23|2015-09-07|Vive Crop Prot Inc|Pyrethroid formulations.|
    GB201115079D0|2011-08-31|2011-10-19|Iota Nanosolutions Ltd|Method of preparing carrier liquids|
    GB201115635D0|2011-09-09|2011-10-26|Univ Liverpool|Compositions of lopinavir and ritonavir|
    GB201115634D0|2011-09-09|2011-10-26|Univ Liverpool|Compositions of lopinavir|
    GB201115633D0|2011-09-09|2011-10-26|Univ Liverpool|Compositions of efavirenz|
    US8609684B2|2011-12-12|2013-12-17|PruGen IP Holdings, Inc.|Solubilization and bioavailability of acetaminophen|
    JP6247685B2|2012-05-16|2017-12-13|メワ・シン|Pharmaceutical composition for delivery of substantially water-insoluble drugs|
    CA2877774C|2012-07-12|2017-07-18|Mallinckrodt Llc|Extended release, abuse deterrent pharmaceutical compositions|
    US20140073678A1|2012-09-12|2014-03-13|Monosol Rx, Llc|Anti-pain and anti-nausea and/or vomiting combinatorial compositions|
    MX2015016675A|2013-06-04|2016-07-15|Vyome Biosciences Pvt Ltd|Coated particles and compositions comprising same.|
    CA2919892C|2013-08-12|2019-06-18|Pharmaceutical Manufacturing Research Services, Inc.|Extruded immediate release abuse deterrent pill|
    US9492444B2|2013-12-17|2016-11-15|Pharmaceutical Manufacturing Research Services, Inc.|Extruded extended release abuse deterrent pill|
    JP6621752B2|2013-10-21|2019-12-18|ソーク インスティテュート フォー バイオロジカル スタディーズ|Mutated fibroblast growth factor1 and methods of use|
    CN105188756B|2013-11-13|2020-06-12|财团法人教育研究基金会|Novel paracetamol compound composition without liver side effect|
    WO2015095391A1|2013-12-17|2015-06-25|Pharmaceutical Manufacturing Research Services, Inc.|Extruded extended release abuse deterrent pill|
    JP6625071B2|2014-03-07|2019-12-25|ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ|Non-drug CRMP2 peptides targeting sodium channels for chronic pain|
    EP2952208A1|2014-06-04|2015-12-09|Universidade de Santiago de Compostela|Hydroalcoholic system for nail treatment|
    CN104042626A|2014-07-01|2014-09-17|李绍明|Bactericidal and bacteriostatic agent|
    ES2809458T3|2014-07-17|2021-03-04|Pharmaceutical Manufacturing Res Services Inc|Liquid filled, abuse deterrent and immediate release dosage form|
    US20160106737A1|2014-10-20|2016-04-21|Pharmaceutical Manufacturing Research Services, Inc.|Extended Release Abuse Deterrent Liquid Fill Dosage Form|
    US10315330B2|2014-12-23|2019-06-11|Dow Global Technologies Llc|Treated porous material|
    WO2016116121A1|2015-01-20|2016-07-28|Merck Patent Gmbh|Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer|
    CN104798772B|2015-03-13|2017-05-24|中国农业科学院农业环境与可持续发展研究所|Pesticide nano-solid dispersion and preparation method thereof|
    JP2018524346A|2015-07-02|2018-08-30|サイヴィタス セラピューティックス，インコーポレイテッド|Triptan powder for pulmonary delivery|
    US10206904B2|2015-07-17|2019-02-19|The Board Of Regents Of The University Of Oklahoma|Licofelone derivatives and methods of use|
    CN105145553A|2015-10-12|2015-12-16|广西田园生化股份有限公司|Indissolvable pesticide solid dispersion composition|
    ES2812155T3|2016-02-02|2021-03-16|Evonik Operations Gmbh|Powder formulations of surfactant substances on water-soluble solid supports, procedures for their production, as well as their use|
    CA3055170A1|2016-03-04|2017-09-08|Charleston Laboratories, Inc.|Pharmaceutical compositions|
    CN109640948A|2016-06-16|2019-04-16|利物浦大学|Chemical composition that|
    RU2619249C1|2016-11-07|2017-05-12|Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук |Composition for seed treatment and method of its production|
    WO2018160772A1|2017-02-28|2018-09-07|The United State Of America, As Represented By The Secretary, Department Of Health & Human Services|Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis|
    EP3601301A1|2017-03-31|2020-02-05|The University of Liverpool|Prodrug compositions|
    TWI725314B|2017-06-15|2021-04-21|松瑞製藥股份有限公司|Methods for producing particles of an active ingredient|
    US20210361639A1|2018-03-02|2021-11-25|The University Of Liverpool|Solid compositions of actives, processes for preparing same and uses of such solid compositions|
    JP6858729B2|2018-05-25|2021-04-14|▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ|New acetaminophen complex composition with no side effects on the liver|
    WO2020135600A1|2018-12-28|2020-07-02|南京善思生物科技有限公司|Nano pesticide formulation and preparation method therefor|
    CN109846821B|2019-01-03|2021-07-06|昆药集团股份有限公司|Artemether nano preparation and preparation method thereof|
    US20220054494A1|2019-03-13|2022-02-24|University Of Pittsburgh - Of The Commonwealth System Of Higher Education|Methods for treating bladder and urethra dysfunction and disease|
    CN110074993A|2019-06-05|2019-08-02|山东大学|A method of preparing ultraviolet absorber nano particle|
    WO2021062012A1|2019-09-25|2021-04-01|Emory University|Use of klk10 and engineered derivatizations thereof|
    WO2021085395A1|2019-10-28|2021-05-06|クミアイ化学工業株式会社|Agrochemical composition and method for producing same|
    WO2021146625A1|2020-01-17|2021-07-22|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Gene therapy for treatment of crx-autosomal dominant retinopathies|
    WO2021225781A2|2020-05-07|2021-11-11|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Aberrant post-translational modificationsin methyl- and propionic acidemia and a mutant sirtuinto metabolize ptms|
    法律状态:
    2011-01-27| MK1| Application lapsed section 142(2)(a) - no request for examination in relevant period|
    优先权:
    申请号 | 申请日 | 专利标题
    GBGB0613925.7A|GB0613925D0|2006-07-13|2006-07-13|Improvements relating to nanodispersions|
    GB0613925.7||2006-07-13||
    AUPCT/EP2007/056560||2007-06-29||
    PCT/EP2007/056560|WO2008006712A2|2006-07-13|2007-06-29|Preparation of nanodispersions|
    PCT/GB2007/050408|WO2008007151A2|2006-07-13|2007-07-13|Processes for preparing pharmaceutical compositions|
    [返回顶部]